Kyle W.H. Chan

Dr. Chan is a cofounder and CSO of NovoMedix, LLC and has over 30 years of experience in drug discovery and development. He was the cofounder and Chief Technology Officer of BioTheryX, Inc., a clinical-stage targeted protein degrader company. Dr. Chan was formerly the head of Discovery Research at Celgene where he built and led technology programs in genomics, proteomics, and informatics as well as successfully managed therapeutic programs in virology, estrogen physiology, and the development of small molecule modulators of epigenetic programming and adult stem cells for regenerative medicine. He has served on scientific and business advisory boards for a number of biotech companies. Dr. Chan received his Ph.D. in electroanalytical chemistry from the University of Illinois, Urbana-Champaign; a post-doctoral fellowship in biophysics from UC San Diego; authored numerous publications and holds over 30 U.S. patents.